SMARCA4 and neoplasm: Particularly, immunotherapies targeting neoantigens from oncogenic driver mutations such as CTNNB1, DDX3X, and SMARCA4 and TAAs which have possible implications in tumor progression such as NEUROG1 and PIK3R3 are attractive for a better outcome in patients.